234089-44-2

Upstream product

• 90-82-4 pseudoephedrine 
• 10313-60-7 3,4-dimethoxyphenylacetyl chloride 
• 93-40-3 (3,4-Dimethoxyphenyl)acetic acid 

Downstream Products

• 250665-92-0 [2S,1'S,2'S]-(+)-2-(3,4-dimethoxyphenyl)-2-[N,N'-bis(1,1-dimethylethoxycarbonyl)hydrazino]-N-(2'-hydroxy-1'-methyl-2'-phenylethyl)-N-methylacetamide 
• 1386350-39-5 (S)-2-(3,4-dimethoxyphenyl)-1-(5-methoxy-2,2-dimethyl-2H-chromen-6-yl)propan-1-one 
• 1192280-95-7 (S)-2-(3,4-dimethoxyphenyl)propionaldehyde 
• 1386351-16-1 (S)-2-(3,4-dimethoxyphenyl)propanoic acid 
• 234089-49-7 (S)-(+)-2-(3,4-dimethoxyphenyl)propanoic acid 
• 773835-29-3 (+)-(3S,4S)-N-benzyl-3-(3,4-dimethoxyphenyl)-6,7-dimethoxy-4-(2-propenyl)-1,2,3,4-tetrahydroisoquinoline 
• 247118-71-4 (+)-(3S,4S)-N-benzyl-3-(3,4-methylenedioxyphenyl)-6,7-dimethoxy-4-(2-propenyl)-1,2,3,4-tetrahydroisoquinoline 
• 247118-63-4 (-)-(1S,2S)-N-benzyl-1,2-bis(3,4-dimethoxyphenyl)-4-pentenylamine 
• 247118-66-7 (-)-(1S,2S)-N-benzyl-2-(3,4-dimethoxyphenyl)-1-(3,4-methylenedioxyphenyl)-4-pentenylamine 
• 247118-62-3 (+)-(S)-2-(3,4-dimethoxyphenyl)-1-(3,4-methylenedioxyphenyl)-4-penten-1-one 
• 247118-59-8 (+)-(S)-1,2-bis(3,4-dimethoxyphenyl)-4-penten-1-one 
• 247118-56-5 (+)-(S)-2-(3,4-dimethoxyphenyl)-4-pentenoic acid 

Relevant academic research and scientific papers

Design, synthesis, and biological evaluation of novel deguelin-based heat shock protein 90 (HSP90) inhibitors targeting proliferation and angiogenesis

Deguelin exhibits potent apoptotic and antiangiogenic activities in a variety of transformed cells and cancer cells. Deguelin also exhibits potent tumor suppressive effects in xenograft tumor models for many human cancers. Our initial studies confirmed that deguelin disrupts ATP binding to HSP90 and consequently induces destabilization of its client proteins such as HIF-1α. Interestingly, a fluorescence probe assay revealed that deguelin and its analogues do not compete with ATP binding to the N-terminus of HSP90, unlike most HSP90 inhibitors. To determine the key parts of deguelin that contribute to its potent HSP90 inhibition, as well as its antiproliferative and antiangiogenic activities, we have established a structure-activity relationship (SAR) of deguelin. In the course of these studies, we identified a series of novel and potent HSP90 inhibitors. In particular, analogues 54 and 69, the B- and C-ring-truncated compounds, exhibited excellent antiproliferative activities with IC50 of 140 and 490 nM in the H1299 cell line, respectively, and antiangiogenic activities in zebrafish embryos in a dose dependent manner (0.25-1.25 μM).

A new general method for the asymmetric synthesis of 4-alkyl-3-aryl- 1,2,3,4-tetrahydroisoquinolines

A highly enantioselective method for the synthesis of 4-alkyl substituted 1,2,3,4-tetrahydroisoquinolines is reported. The key step relies on the asymmetric synthesis of α-alkylarylacetic acids by alkylation of their corresponding amides employing (S,S)-(+)-pseudoephedrine as chiral inductor. Subsequent Friedel-Crafts acylation, stereocontrolled reductive amination and Pictet-Spengler cyclization affords the title compounds in excellent yields and enantioselectivities.

The first stereocontrolled synthesis of 12-methylhexahydrobenzo [c]phenanthridine alkaloids

12-Methyl B/C hexahydrobenzo[c]phenanthridines have been synthesized stereoselectively starting from chiral nonracemic 2-aryl-4-pentenoic acids prepared by asymmetric allylation of (+)-(S,S)-pseudoephedrine-based arylacetamide enolates. Subsequent transfo